Latest Period
Q1 2026
Security Snapshot
Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) Institutional Ownership
CUSIP: 67577R102
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
76
Shares (Excl. Options)
44,276,162
Price
$4.55
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- IRD on Nasdaq
- Shares outstanding
- 81,377,060
- Price per share
- $4.67
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 44,276,162
- Total reported value
- $201,458,238
- % of total 13F portfolios
- 0%
- Share change
- +17,181,341
- Value change
- +$79,524,140
- Number of holders
- 76
- Price from insider filings
- $4.67
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- IRD - Opus Genetics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 67577R102.
- 76 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 58 to 76 between Q4 2025 and Q1 2026.
- Reported value moved from $55,903,061 to $201,458,238.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 76 institutions filings for Q1 2026.
Security key
67577R102
Latest holder period
Q1 2026
13F holders
76
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
IRD full holder history
Opus Genetics, Inc. SEC filings
Opus Genetics, Inc. company facts
Opus Genetics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 67577R102:
Significant Owners of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% | 0% | $43,444,313 | +$8,147,476 | 8,830,145 | +23% | Perceptive Advisors LLC | 31 Mar 2026 |
| Caligan Partners LP | 8.5% | $29,889,138 | 6,075,028 | Caligan Partners LP | 31 Mar 2026 | |||
| Adage Capital Management, L.P. | 8.5% | $29,666,493 | 6,029,775 | Adage Capital Management, L.P. | 31 Mar 2026 | |||
| BALYASNY ASSET MANAGEMENT L.P. | 7.2% | -3.3% | $25,143,035 | 5,110,373 | 0% | Balyasny Asset Management L.P. | 31 Mar 2026 | |
| Nantahala Capital Management, LLC | 6.5% | -35% | $23,808,987 | -$11,238,663 | 4,839,225 | -32% | Nantahala Capital Management, LLC | 31 Mar 2026 |
| Foundation Fighting Blindness Retinal Degeneration Fund | 4.7% | -42% | $17,709,439 | -$7,939,000 | 3,792,171 | -31% | Foundation Fighting Blindness Retinal Degeneration Fund | 18 May 2026 |
| BIOS Fund III, LP | 4.5% | $18,122,471 | 3,683,429 | AARON G.L. FLETCHER | 12 May 2026 |
As of 31 Mar 2026, 76 institutional investors reported holding 44,276,162 shares of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD). This represents 54% of the company’s total 81,377,060 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Caligan Partners LP | 7.5% | 6,075,028 | 2% | $27,641,377 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.4% | 6,029,775 | +446% | 0.04% | $27,435,476 |
| BIOS Capital Management, LP | 4.5% | 3,683,429 | 0% | 32% | $16,759,602 |
| Balyasny Asset Management L.P. | 3.3% | 2,718,029 | 0% | 0.02% | $12,367,032 |
| MILLENNIUM MANAGEMENT LLC | 3.2% | 2,630,432 | +31% | 0.01% | $11,968,466 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3% | 2,449,987 | 0% | 0% | $11,147,441 |
| MARSHALL WACE, LLP | 2.8% | 2,313,380 | +1367% | 0.01% | $10,525,879 |
| Boxer Capital Management, LLC | 2.8% | 2,250,000 | 1.3% | $10,237,500 | |
| ADAR1 Capital Management, LLC | 2.3% | 1,849,004 | +4523% | 0.51% | $8,412,968 |
| PERCEPTIVE ADVISORS LLC | 2.3% | 1,835,842 | -58% | 0.17% | $8,353,081 |
| Nantahala Capital Management, LLC | 2.1% | 1,681,330 | -65% | 0.48% | $7,650,052 |
| Woodline Partners LP | 1.7% | 1,354,030 | 0.02% | $6,160,837 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.5% | 1,189,113 | 0.13% | $5,410,464 | |
| FARALLON CAPITAL MANAGEMENT LLC | 1.2% | 1,000,000 | 0.03% | $4,550,000 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1% | 823,383 | +308% | 0% | $3,746,393 |
| Bleichroeder LP | 0.91% | 736,842 | 0% | 0.58% | $3,352,631 |
| Mink Brook Asset Management LLC | 0.73% | 590,552 | -65% | 1.5% | $2,687,012 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.66% | 538,347 | +6.6% | 0% | $2,451,169 |
| Trails Edge Capital Partners, LP | 0.61% | 500,000 | 0.54% | $2,275,000 | |
| AMERIPRISE FINANCIAL INC | 0.48% | 388,491 | 0% | $1,767,634 | |
| GOLDMAN SACHS GROUP INC | 0.4% | 326,809 | 0% | $1,486,981 | |
| GREAT POINT PARTNERS LLC | 0.4% | 324,340 | 0.36% | $1,475,747 | |
| VANGUARD FIDUCIARY TRUST CO | 0.35% | 281,801 | 0% | 0% | $1,282,195 |
| UBS Group AG | 0.32% | 257,649 | +187% | 0% | $1,172,303 |
| STATE STREET CORP | 0.25% | 199,953 | +15% | 0% | $909,786 |
Institutional Holders of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 44,276,162 | $201,458,238 | +$79,524,140 | $4.55 | 76 |
| 2025 Q4 | 27,812,069 | $55,903,061 | +$17,653,005 | $2.01 | 58 |
| 2025 Q3 | 19,026,274 | $31,911,867 | +$2,765,658 | $1.65 | 46 |
| 2025 Q2 | 17,503,196 | $16,482,508 | +$2,741,389 | $0.94 | 43 |
| 2025 Q1 | 14,560,311 | $14,686,745 | +$11,049,669 | $0.98 | 46 |
| 2024 Q4 | 3,678,848 | $4,378,207 | +$106,956 | $1.19 | 42 |
| 2024 Q3 | 2,531,596 | $3,315,513 | -$283,780 | $1.31 | 37 |
| 2024 Q2 | 2,696,097 | $4,126,103 | -$1,250,857 | $1.53 | 37 |
| 2024 Q1 | 3,374,307 | $6,780,798 | -$925,460 | $2.01 | 48 |
| 2023 Q4 | 3,712,141 | $11,173,334 | -$177,249 | $3.01 | 48 |
| 2023 Q3 | 3,768,545 | $12,624,748 | +$43,437 | $3.35 | 50 |
| 2023 Q2 | 3,675,838 | $15,952,413 | +$1,001,477 | $4.34 | 49 |
| 2023 Q1 | 3,457,077 | $12,962,551 | +$1,457,390 | $3.75 | 40 |
| 2022 Q4 | 3,099,588 | $10,946,085 | +$1,241,957 | $3.53 | 34 |
| 2022 Q3 | 2,825,667 | $5,686,000 | +$828,901 | $2.01 | 33 |
| 2022 Q2 | 2,407,242 | $4,623,000 | +$385,937 | $1.92 | 35 |
| 2022 Q1 | 2,052,047 | $6,623,000 | -$430,212 | $3.23 | 33 |
| 2021 Q4 | 2,169,473 | $8,073,000 | +$1,421,030 | $3.73 | 32 |
| 2021 Q3 | 1,679,507 | $8,621,000 | +$3,116,790 | $5.15 | 26 |
| 2021 Q2 | 1,038,443 | $5,482,000 | +$532,990 | $5.28 | 28 |
| 2021 Q1 | 912,180 | $5,265,087 | -$7,635,114 | $5.81 | 21 |
| 2020 Q4 | 2,209,512 | $14,469,013 | +$1,044,013 | $6.52 | 9 |